SCHEMBL166010

SCHEMBL166010

COC(=O)c1cc(C(F)(F)F)c(C(Br)Br)cc1OC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CFTR P13569 6/20 0.40
NOTUM Q6P988 2/20 0.39
SOS1 Q07889 1/20 0.36
POLB P06746 1/20 0.35
CFD P00746 2/20 0.33
BACE1 P56817 1/20 0.33
S1PR1 P21453 1/20 0.33
MAPT P10636 1/20 0.33
TNFSF11 O14788 1/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167840 0.81 POLB (0.38) KDM4EUSP2ALDH1A1HPGDCYP2C19
SCHEMBL167207 0.81 POLB (0.48) KDM4EUSP2ALDH1A1HPGDCYP2C19
SCHEMBL168791 0.80 GAA (0.46) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL167487 0.79 KDM4E (0.41) KDM4EUSP2ALDH1A1HPGDCYP2C19
SCHEMBL7800039 0.75 S1PR1 (0.47) KDM4EALDH1A1HPGDCFTRNOTUM
SCHEMBL17185142 0.74 CYP4F2 (0.39) KDM4EUSP2ALDH1A1HPGDCYP2C19
SCHEMBL15920408 0.71 CFTR (0.57) KDM4EALDH1A1HPGDHSD17B10CFTR
SCHEMBL27781533 0.71 KDM4E (0.60) KDM4EUSP2ALDH1A1HPGDCYP2C19
SCHEMBL5943417 0.71 KDM4E (0.73) KDM4EUSP2ALDH1A1HPGDCYP2C19
SCHEMBL17978941 0.71 NOTUM (0.61) KDM4EALDH1A1HPGDHSD17B10NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 KDM4E 1447/4885USP2 1681/4885ALDH1A1 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.